Information

You are on the new improved site. You can view the old site in view-only mode here until June 27, 2026

loading
Still Awaiting Biosimilars Path to Market;Motavizumab Rejected by FDA Advisory Committee;Avastin Approval for Breast Cancer Revoked;Genzyme Has Another Contamination Problem;EMA to Release Adverse Effects Data;FDA Releases List of Latest Safety Issues